Free Trial
OTCMKTS:GSGTF

GenSight Biologics (GSGTF) Stock Price, News & Analysis

GenSight Biologics logo
$0.24 0.00 (0.00%)
As of 05/15/2025

About GenSight Biologics Stock (OTCMKTS:GSGTF)

Key Stats

Today's Range
$0.24
$0.24
50-Day Range
$0.24
$0.24
52-Week Range
$0.32
$0.32
Volume
N/A
Average Volume
583 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Receive GSGTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GenSight Biologics and its competitors with MarketBeat's FREE daily newsletter.

GSGTF Stock News Headlines

GenSight Biologics SA (G49N) Gets a Hold from Kepler Capital
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

GSGTF Stock Analysis - Frequently Asked Questions

GenSight Biologics' stock was trading at $0.24 on January 1st, 2025. Since then, GSGTF shares have increased by 0.0% and is now trading at $0.24.
View the best growth stocks for 2025 here
.

Shares of GSGTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:GSGTF
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:GSGTF) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners